
Profitability, historical returns, and peer comparisons.
According to Novavax, Inc.’s latest financial reports and current stock price. The company's current ROE is 159.85%. This represents a change of 326.26% compared to the average of 37.50% of the last 4 quarters.
The mean historical ROE of Novavax, Inc. over the last ten years is 570.30%. The current 159.85% ROE has changed -71.97% with respect to the historical average. Over the past ten years (40 quarters), NVAX's ROE was at its highest in in the December 2016 quarter at 1.03%. The ROE was at its lowest in in the March 2025 quarter at -685.65%.
Average
570.30%
Median
89.90%
Minimum
-344.65%
Maximum
5.05%
Discovering the peaks and valleys of Novavax, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual ROE = 5.05%
Minimum Annual Increase = -9514.06%
Minimum Annual ROE = -344.65%
| Year | ROE | Change |
|---|---|---|
| 2025 | -344.65% | -1246.71% |
| 2024 | 30.06% | -60.47% |
| 2023 | 76.03% | -26.73% |
| 2022 | 103.76% | -79.07% |
| 2021 | 495.84% | -843.55% |
| 2020 | -66.69% | -195.35% |
| 2019 | 69.94% | -36.42% |
| 2018 | 110.01% | -39.10% |
| 2017 | 180.64% | -96.42% |
| 2016 | 5.05% | -9514.06% |
The current ROE of Novavax, Inc. (NVAX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-79.52%
5-year avg
72.21%
10-year avg
570.30%
Novavax, Inc.’s ROE is greater than Valneva SE (-152.15%), greater than Vaxcyte, Inc. (-37.57%), greater than GeoVax Labs, Inc. (-743.66%), greater than Arcturus Therapeutics Holdings Inc. (-46.54%), greater than Moderna, Inc. (-39.20%), greater than Oragenics, Inc. (-144.23%), greater than Inovio Pharmaceuticals, Inc. (-1005.80%), greater than BioNTech SE (-9.16%), greater than Emergent BioSolutions Inc. (-35.91%), greater than Scinai Immunotherapeutics Ltd. (-26.63%),
| Company | ROE | Market cap |
|---|---|---|
| -152.15% | $506.36M | |
| -37.57% | $9.57B | |
| -743.66% | $1.64M | |
| -46.54% | $284.66M | |
| -39.20% | $89.58B | |
| -144.23% | $1.67M | |
| -1005.80% | $124.02M | |
| -9.16% | $22.03B | |
| -35.91% | $345.33M | |
| -26.63% | $243.32K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novavax, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novavax, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Novavax, Inc.'s ROE?
How is the ROE calculated for Novavax, Inc. (NVAX)?
What is the highest ROE for Novavax, Inc. (NVAX)?
What is the 3-year average ROE for Novavax, Inc. (NVAX)?
What is the 5-year average ROE for Novavax, Inc. (NVAX)?
How does the current ROE for Novavax, Inc. (NVAX) compare to its historical average?